First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody–drug conjugate targeting c-Met, in patients with advanced solid tumors
John H. Strickler, Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, Todd M. Bauer, Huibin Yue, Monica Motwani, Apurvasena Parikh, Edward B. Reilly, Daniel Afar, Louie Naumovski, Karen Kelly
Fingerprint
Dive into the research topics of 'First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody–drug conjugate targeting c-Met, in patients with advanced solid tumors'. Together they form a unique fingerprint.